On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

What Happened: Alvarez's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 758 shares of Eli Lilly. The total transaction ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

US pharma major Eli Lilly is raising the list price for its obesity drug Mounjaro (tirzepatide) in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump ...